

**THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.**



30 July 2025

**ANANDA PHARMA PLC**  
("Ananda" or the "Company")

### **Notice of Annual General Meeting**

Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that notice convening the Company's Annual General Meeting ("AGM") for 2.00pm BST on 26 August 2025 at the offices of Arch Law, Level 2, Huckletree, 8 Bishopsgate, London, EC2N 4BQ, has been sent to shareholders of the Company.

Full details of the resolutions proposed to the shareholders are available within the Notice of Meeting, available at <https://investors.anandapharma.co.uk/s/0e221d> under the Notices and Meetings tab.

Melissa Sturgess will be giving a corporate update presentation and Q&A session via the Company's InvestorHub on 12<sup>th</sup> of August 2025 at 12.00pm.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the webinar page up until 12.00pm on 11<sup>th</sup> of August 2025, or at anytime during the live presentation.

Investors can sign up to the webinar for free via:  
<https://investors.anandapharma.co.uk/s/09bdfb>.

## **About Ananda Pharma**

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR). The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

For more information, please visit our [website](#):

To stay up to date with Ananda's news please follow our social media channels:

- Investor Hub: <https://investors.anandapharma.co.uk/s/ea8f93>
- Instagram: <https://www.instagram.com/anandapharmapl/>
- LinkedIn: <https://www.linkedin.com/company/anandapharma>
- X: <https://twitter.com/AnandaPlc>
- Investor Meet Company:  
<https://www.investormeetcompany.com/ananda-pharma-plc/register-investor>

-Ends-

For the purposes of UK MAR, the Directors of the Company accept responsibility for the contents of this announcement.

### **ANANDA PHARMA PLC**

+44 (0)7463 686 497

[ir@anandapharma.co.uk](mailto:ir@anandapharma.co.uk)

Chief Executive Officer

Melissa Sturgess

Finance Director

Jeremy Sturgess-Smith

### **SP ANGEL CORPORATE FINANCE LLP**

Corporate Broking

+44 (0)20 3470 0534

Abigail Wayne  
Rob Rees

[Abigail.wayne@spangel.co.uk](mailto:Abigail.wayne@spangel.co.uk)  
[Rob.ress@spangel.co.uk](mailto:Rob.ress@spangel.co.uk)

**Corporate Finance**

+44 (0)20 3470 0470

Richard Morrison  
Josh Ray

**VIRIDIAN CAPITAL ADVISORS (US)**

+1 (646) 330-0704

Scott Greiper

[sgreiper@viridianca.com](mailto:sgreiper@viridianca.com)

**YELLOW JERSEY PR**

+44 (0)20 3004 9512

Sarah MacLeod  
Charles Goodwin  
Zara McKinlay

[ananda@yellowjerseypr.com](mailto:ananda@yellowjerseypr.com)

<https://investors.anandapharma.co.uk/link/y05zke>